Pear Therapeutics, Inc.

Thimble Point Acquisition Corp (Nasdaq: THMA), a blank-check company sponsored by Thimble Point LLC and formed in 2021, filed an 8-K with the SEC on November 30, 2021 in connection with its proposed business combination with Pear Therapeutics, Inc., a commercial-stage prescription digital therapeutics company operating in the digital health sector. Pear Therapeutics developed FDA-authorized software-based treatments targeting substance use disorder and other chronic conditions, placing the deal within the healthcare technology space. The transaction represented a notable convergence of SPAC capital markets activity and the emerging prescription digital therapeutics industry. The combined company subsequently traded on Nasdaq under the ticker PEAR following closing of the de-SPAC transaction. For complete filing history, deal terms, and real-time status data on THMA and hundreds of other SPACs, create a free account at SpacDesk.